Detalhe da pesquisa
1.
Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
Br J Clin Pharmacol
; 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38500445
2.
Oral docetaxel plus encequidar - A pharmacokinetic model and evaluation against IV docetaxel.
J Pharmacokinet Pharmacodyn
; 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38504032
3.
A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment.
J Formos Med Assoc
; 123(1): 55-61, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37666718
4.
A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
Future Oncol
; 19(11): 753-761, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129584
5.
Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results.
Int J Mol Sci
; 25(1)2023 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38203603
6.
Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.
Br J Clin Pharmacol
; 88(5): 2396-2407, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34907578
7.
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
Future Oncol
; 18(27): 2999-3009, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35924546
8.
Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.
J Formos Med Assoc
; 120(3): 956-964, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33077341
9.
Correction: Oral docetaxel plus encequidar - a pharmacokinetic model and evaluation against IV docetaxel.
J Pharmacokinet Pharmacodyn
; 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38744774
10.
Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities.
Adv Ther
; 41(2): 847-856, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38010606
11.
A Sensitive Assay for Unbound Docetaxel Using Ultrafiltration plus HPLC-MS and Its Application to a Clinical Study.
Pharmaceutics
; 16(5)2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38794263
12.
A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.
Infect Dis Ther
; 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38771550
13.
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.
J Hematol
; 13(1-2): 12-22, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38644985
14.
An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1.
Front Oncol
; 13: 1173467, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182173
15.
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.
Front Oncol
; 13: 1109866, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36776307
16.
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
Exp Hematol Oncol
; 12(1): 55, 2023 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37344895
17.
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study.
Ther Adv Med Oncol
; 15: 17588359231183680, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37492633
18.
Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.
Viruses
; 14(6)2022 05 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35746606
19.
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results.
Pharmaceutics
; 14(10)2022 Oct 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36297594
20.
Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan.
Adv Ther
; 39(2): 910-922, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34910280